Antonio Benedetti is appointed as Kuano’s new Chairperson

Cambridge, UK, 23 June 2022 - Kuano is delighted to announce Antonio Benedetti as its new Executive Chairman. He brings more than 25 years of executive experience in the Pharmaceutical and Automotive Industries. Before joining Kuano as Chairman, Mr Benedetti has been CEO of Cycle Pharmaceuticals for 6 years. Under his leadership, Cycle has developed and launched several orphan drugs in the US, where patients are supported by a newly created HUB, and has expanded its presence globally. Before Cycle, Mr Benedetti has been the CEO of Magirus Gmbh, one of the largest Fire Fighting equipment manufacturers in the world, part of CNH Industrial Group. Formerly, he was Group CFO at Archimica Group Holding BV, a global API contract manufacturer. Antonio holds a Master Degree in Economics and has started his career in Fiat Group Automobiles, where he covered several executive positions mostly on international assignments.

Vid Stojevic, CEO says,

“Having Antonio’s commercial input is of real value. Kuano will benefit from his skills and executive experience in strategic business planning at a time of commercialisation for the company. It’s great to have him on board and I take great pleasure in welcoming him to the team.”

Antonio Benedetti,

“Kuano’s technology is ground-breaking with their unique approach to quantum chemistry, and expertise in AI/ML placing them at the forefront of drug discovery. I join the team at an exciting juncture: their technology is validated and commercial strategy becoming realised. I look forward to contributing to their commercial growth, and helping them on their journey to create first-in-class drugs for intractable enzyme targets.”